Business Wire

Stone Harbor Investment Partners Introduces Emerging Markets Climate Impact Debt Fund

18.6.2025 23:05:00 EEST | Business Wire | Press release

Share

Stone Harbor Investment Partners, an investment manager of Virtus Investment Partners, Inc. (NYSE: VRTS), has launched the Stone Harbor Emerging Markets Climate Impact Debt (Bloomberg: STHEMDI) (the “Fund”), a UCITS fund classified as Article 9 under the Sustainable Finance Disclosure Regulation (SFDR) that addresses decarbonization efforts occurring in Emerging Markets (EM) while seeking to deliver attractive long-term total returns for investors.

The Fund invests in sustainable debt issued with proceeds dedicated to environmental activities, assets, projects or expenditures, with social bonds also permissible, of EM corporate, sovereign, quasi-sovereign and supranational issuers in hard currency. The Fund, with a sustainable objective to promote the transition towards an environmentally and socially sustainable economy, seeks to outperform the J.P Morgan EM Credit Green, Social and Sustainability Bond Diversified Index (GESSIE EM Credit Div USD Hedged).

"Stone Harbor has incorporated sustainability factors into the EM debt investment process for well over a decade, and as issuance of emerging markets labelled bonds has grown alongside demand from our clients for sustainable investment solutions, we have responded with a comprehensive platform to cover the full spectrum of emerging markets fixed income exposure,” said James E. Craige, CFA, Stone Harbor’s chief investment officer and head of Emerging Markets, who oversees the management of the Fund. “The new Fund brings together our specialist investment skills in emerging markets with a sustainable investment framework that meets the Article 9 requirements of institutional investors.”

In addition to Craige, the Stone Harbor investment team managing the Fund includes Deputy Chief Investment Officer Stuart Slater-Booth and Portfolio Managers Steffen Reichold, Richard Lange and Darin Batchman.

“The market for emerging markets green and sustainable bonds has been developing rapidly and now offers broad diversification in liquid markets as the Fund aims to provide access to measurable, high-impact investments while at the same time offering attractive risk-adjusted returns,” Reichold said.

The Fund’s investments are identified through the Stone Harbor SFDR sustainable investments framework and complements the firm’s Article 8 UCITS fund, the Stone Harbor Emerging Markets Corporate Debt Fund.

“To support our sustainability strategy, Stone Harbor helped transition our portfolio from traditional EM debt investments to a strategy focused on green and sustainable bonds that is managed in line with Article 9 requirements,” said Marius Daheim of BarmeniaGothaer Asset Management, based in Cologne, Germany.

About Stone Harbor Investment Partners

Stone Harbor Investment Partners is a global credit specialist with three decades of expertise in emerging and developed markets debt. Stone Harbor’s investment team – portfolio managers, credit analysts, economists, quantitative analysts, and risk management professionals – engages in disciplined and regular collaboration to carefully construct their global macroeconomic outlook and strategic allocation framework. As a research-driven firm, Stone Harbor drills deeply into the fundamentals to determine the attractiveness of individual credits, currencies, interest rates, and yield curves to find the best investments within select asset classes.

About Virtus Investment Partners, Inc.

Virtus Investment Partners (NYSE: VRTS) is a distinctive partnership of boutique investment managers singularly committed to the long-term success of individual and institutional investors. We provide investment products and services from our investment managers, each with a distinct investment style and autonomous investment process, as well as select subadvisers. Investment solutions are available across multiple disciplines and product types to meet a wide array of investor needs. Additional information about our firm, investment partners, and strategies is available at virtus.com.

Risk Considerations

Interest Rate:The values of debt instruments may rise or fall in response to changes in interest rates, and this risk may be enhanced for securities with longer maturities.Currency Rate:Fluctuations in the exchange rates between the U.S. dollar and foreign currencies may negatively affect the value of the portfolio’s shares. Emerging Markets Risk:Investments in emerging markets may involve a higher degree of risk. Assets may not be properly held in custody and, as a result, may be lost. It may be more difficult to sell assets at a fair price in emerging markets. ESG:The interpretation of ESG and sustainability criteria is subjective meaning that the fund may invest in companies which similar funds do not (and thus perform differently) and which do not align with the personal views of any individual investor. The portfolio's consideration of ESG factors could cause the portfolio to perform differently from other portfolios. While Stone Harbor Investment Partners believes that the integration of ESG factors into the portfolio's investment process has the potential to contribute to performance, ESG factors may not be considered for every investment decision and there is no guarantee that the integration of ESG factors will result in better performance. There is no guarantee that ESG integration and engagement will enhance the quality of asset allocation or portfolio construction. ESG characteristics and risks could have a materially positive or negative impact on the performance of a Fund.Credit Risk:The issuers of securities or similar instruments that we buy may not be able to make payments, which could lead to an investment loss. This risk is greater for investments with a medium or low credit rating.Counterparty:There is risk that a party upon whom the portfolio relies to complete a transaction will default.Derivatives Risk:A small movement in the value of the underlying asset may cause a large movement in the value of the derivative which can result in a loss to the Fund.Investment Risk:Investing is subject to risk, including the risk of possible loss of principal. Prospectus: For more information in relation to these and other risks, please refer to the “Characteristics and Risks of Securities and Investment Techniques” section of the prospectus.

The fund described above is a sub-fund of Stone Harbor Investment Funds plc (the “Fund”), an investment company with variable capital incorporated with limited liability in Ireland and established as an umbrella fund with segregated liability between the funds pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011 (as amended). Please refer to the current prospectus and to the relevant PRIIPS KID/KIID before making any final investment decision. The prospectus for the Fund, the PRIIPS KID/KIID for each of the share classes of the Fund (in an official language of the relevant jurisdiction), and the summary of investor rights (in English) are available online at globalfunds.virtus.com or may be received upon request via email by contacting legal@shipemd.com. Share classes of certain sub-funds are currently notified for marketing into a number of EU Member States under the UCITS Directive. A decision may be taken at any time to terminate the arrangements made for the marketing of the sub-fund in any Member State in which it is currently marketed. In such circumstances, Shareholders in the affected Member State will be notified of this decision and will be provided with the opportunity to redeem their shareholding in the Fund free of any charges or deductions for at least 30 working days from the date of such notification. The sub-funds have not been registered under the United States Investment Company Act of 1940, as amended, or the United States Securities Act of 1933, as amended. The Fund is not available for sale in the U.S. or to U.S. Persons. This information and material shown on this page are for information only and do not constitute an offering or investment, legal, tax or other advice. The information shown on this page constitutes an advertising document in certain jurisdictions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250618427695/en/

Contacts

Laura Parsons, Media Relations
(860) 503-1382
laura.parsons@virtus.com

Jaime Doyle, Media Relations
(973) 944-8105
jdoyle@jconnelly.com

Mark Weiller, Stone Harbor
(212) 548-1130
mweiller@shipemd.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye